Skip to main content Back to Top
Advertisement

11/5/2021

Epoprostenol Injection

Products Affected - Description

    • Epoprostenol sodium lyophilized powder for injection, Sun Pharma, 0.5 mg, single dose vial, NDC 62756-0059-40
    • Epoprostenol sodium lyophilized powder for injection, Sun Pharma, 1.5 mg, single dose vial, NDC 62756-0060-40
    • Epoprostenol sodium lyophilized powder for injection, Teva, 0.5 mg, single dose vial, NDC 00703-1985-01
    • Epoprostenol sodium lyophilized powder for injection, Teva, 1.5 mg, single dose vial, NDC 00703-1995-01

Reason for the Shortage

    • Actelion Pharmaceuticals has Veletri available.
    • GlaxoSmithKline has Flolan available.
    • Sun Pharma did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.

Available Products

    • Flolan lyophilized powder for injection, GlaxoSmithKline, 0.5 mg, single dose vial, NDC 00173-0517-00
    • Flolan lyophilized powder for injection, GlaxoSmithKline, 1.5 mg, single dose vial, NDC 00173-0519-00
    • Veletri lyophilized powder for injection, Actelion Pharmaceuticals, 0.5 mg, single dose vial, NDC 66215-0403-01
    • Veletri lyophilized powder for injection, Actelion Pharmaceuticals, 1.5 mg, single dose vial, NDC 66215-0402-01

Estimated Resupply Dates

    • Sun Pharma has epoprostenol sodium 0.5 mg vials in limited supply and the company estimates additional product will be available in early-2022. The 1.5 mg vials are on back order and the company estimates a release date of early-2022.
    • Teva has epoprostenol sodium 0.5 mg and 1.5 mg vials on back order and the company cannot estimate a release date.

Updated

Updated November 5, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. Created September 15, 2021 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.